Lithuanian Lung Cancer Implementation Guide
0.0.1 - ci-build
Lithuanian Lung Cancer Implementation Guide, published by Lithuanian Medical Library. This guide is not an authorized publication; it is the continuous build for version 0.0.1 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7LT/ig-lt-lung/ and changes regularly. See the Directory of published versions
Dabartiniam puslapiui nėra vertimo puslapio, todėl jis pateiktas numatytąja kalba
This page describes the FHIR profiles defined in the Lithuanian Lung Cancer Implementation Guide. The profiles model the LDCT (low-dose chest computed tomography) screening pathway — from the imaging report container through individual findings to the LUNG-RADS assessment and follow-up recommendations.
| Profile | Description |
|---|---|
| LungReportLtLung | Overall LDCT diagnostic report wrapping the lung composition and aggregating all structured results. Based on ImagingReportLt from the base IG. |
| LungCompositionLtLung | Lung-specific imaging composition with sections for findings (nodules, incidental findings), impression (LUNG-RADS), and recommendations. Based on ImagingCompositionLt. |
| Profile | Description |
|---|---|
| LungRadsAssessmentLtLung | LUNG-RADS category assessment (0, 1, 2, 3, 4A, 4B, 4X) with optional S modifier for significant incidental findings. |
| PulmonaryNoduleObservationLtLung | Individual pulmonary nodule observation with type (solid, part-solid, ground-glass, calcified, cavitary), lung lobe location, morphology (spiculation, irregular margins, pleural association), and size/volume measurements. |
| IncidentalFindingLtLung | Significant incidental finding detected during LDCT — covers pulmonary findings (emphysema, bronchiectasis, pleural changes) and extra-pulmonary findings (coronary calcification, aortic aneurysm, mediastinal mass, etc.). |
| LungRecommendationObservationLtLung | Follow-up recommendation based on the LUNG-RADS category (repeat screening, follow-up interval, specialist consultation). |
The lung cancer screening pathway relies on resources from other Lithuanian FHIR IGs: